Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers
Authors:
- 9 November 2017
- journal article
- letter
- Published by Wiley in Movement Disorders
- Vol. 33 (2) , 335-338
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPTNeurobiology of Aging, 2013
- The neuropathology of genetic Parkinson's diseaseMovement Disorders, 2012
- Screening for LRRK2 R1441 mutations in a cohort of PSP patients from GermanyEuropean Journal of Neurology, 2009
- Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degenerationJournal of the Neurological Sciences, 2008
- Parkinsonism, Lrrk2 G2019S, and tau neuropathologyNeurology, 2006
- Lrrk2 R1441 substitution and progressive supranuclear palsyNeuropathology and Applied Neurobiology, 2006
- Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's DiseaseNeuron, 2004
- Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic PathologyNeuron, 2004
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996
- Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related DisordersJournal of Neuropathology & Experimental Neurology, 1996